Diabete MellitusRESET-INSPIRENCT07861191
RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
An observational study of Diabete Mellitus and MASLD, run by National University Health System, Singapore at 1 site in Singapore.
Trial summary
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Read more about this study
- Who is it for?
- Ages 21 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Diabete Mellitus, MASLD
- How many people
- 270 participants
- Where
- 1 siteSingapore
- Study dates
- 27 Jul 2026to 31 Dec 2026
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Recruitment is in Singapore as follows: 1. Flyer: The flyer, which contains a QR code to our landing page and the study contact number, will be distributed at various outreach events such as the Standard Chartered Marathon Race Pack Collection. Permissions will be obtained from the event organizers (if necessary, especially for non-NUS events), before distribution of flyers. 2. Word of Mouth: We are planning to inform participants of Project RESET about this study and encourage them to inform their family and friends to participate in it. 3. Project RESET Cohort: About 5000 people have signed up for Project RESET and we can look to recruit these people for this study if they have given their consent to be contacted for other studies. 4. Expression of interest online form: There was an online Town Hall conducted for all Project RESET participants on 11th and 12th of February 2026 and Project INSPIRE was introduced there with a link and QR code to Project INSPIRE.
Who may be able to join
- Adults aged between 21 and 70 years (including 70 yrs old) at the time of screening
- Able to speak and understand English
- No past history of acute myocardial infarction (heart attack), stroke or heart failure
- Able to understand and voluntarily provide written informed consent prior to any study specific procedures.
- No current diagnosis of type 1 or type 2 diabetes, and not taking glucose-lowering medications.
- Willing and able to comply with all scheduled study procedures.
Who cannot join
- Known diagnosis of diabetes mellitus (type 1 or type 2), or use of antidiabetic medication.
- Current or recent (within 3 months) use of medications known to affect glucose, including but not limited to corticosteroids.
- Known history of liver disease or abnormal liver function deemed clinically significant by the investigator who is a medical doctor.
- Renal impairment, defined as eGFR ≤ 60mL/min/1.73m^2
- Known pregnancy, plans to become pregnant during the study period, or currently breastfeeding, or
- Known allergy or intolerance to CGM adhesives or inability to comply with CGM sensor placement, or
- Any medical, psychiatric, or social condition that, in the opinion of the investigator, would interfere with the participant's ability to adhere to study procedures or would pose additional risk.
- Participation in another interventional clinical trial within the past 3 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
MD6, Centre for Translational Medicine, 14 Medical Drive, Singapore 117599
Singapore, Singapore, 117599
Benjamin Jia-Hui Loh, PhD, +65-89430875, benjaminloh82@nus.edu.sg
Beverly Jingmei Wong, BSc, +65-80258009, beverlyw@nus.edu.sg
About this study
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
Read the detailed description
Insulin resistance is a key factor in the development of metabolic-associated steatotic liver disease (MASLD) and cardiovascular-metabolic disease (CVMD). It occurs when tissues such as skeletal muscle, fat, and liver respond poorly to insulin, leading to metabolic imbalance.
In skeletal muscle, insulin resistance reduces glucose uptake after meals, leaving blood sugar elevated for longer. This contributes to stress on pancreatic beta-cells and damages blood vessels and the heart. In adipose tissue, impaired insulin action increases the release of free fatty acids, which build up in the liver, muscle, and heart, worsening fat accumulation and mitochondrial dysfunction. In the liver, insulin resistance prevents proper suppression of glucose production, causing fasting hyperglycemia and accelerating progression to diabetes.
Together, these tissue-specific changes drive hyperglycemia, abnormal lipid levels, inflammation, and vascular dysfunction-hallmarks of metabolic syndrome. Early detection and targeted management of insulin resistance are therefore crucial for preventing MASLD and CVMD This study will enable evaluation of CGM-derived metrics against established OGTT-based measures, providing insights into early metabolic dysfunction in individuals without diabetes under both controlled and real-world conditions.
- Conditions
- Diabete Mellitus, MASLD
- Keywords
- insulin resistance, Insulin sensitivity, Continuous Glucose Monitor, OGTT, MASLD, Cardiovascular Metabolic Disease, Prediabetes, Diabetes
- Medical subject headings
- Diabetes Mellitus, Insulin Resistance, Prediabetic State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Main Study Cohort | There is only one study cohort for Project Inspire, and no interventions are done on them as this is an Observational study. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Continuous Glucose Monitor data
The continuous Glucose Monitor measures glucose in the interstitial fluid under the skin and outputs it in units of mmol/L
Measured: 15 days
Blood Glucose
Blood glucose is measured at all timepoints for the OGTT and is output in mmol/L
Measured: 2 hours
Insulin
Insulin in the blood is measured at all timepoints of the OGTT and output in mU/L
Measured: 2 hours
C-Peptide
C-Peptide levels in the blood is measured at all timepoints of the OGTT and output as ng/ml
Measured: 2 hours
Secondary outcomes (48)
HBA1C
Blood HBA1C measured in the fasting blood sample during the OGTT and output in percentage (%)
Measured: At the start of OGTT
hs-CRP
hs-CRP measured in the fasting blood sample and output as mg/L.
Measured: At the start of the OGTT
ESR (Alifax)
Erythrocyte Sedimentation Rate (Blood) measures ESR (Alifax) and outputs in mm.hr
Measured: At the start of OGTT
Total Cholesterol
Blood Total Cholesterol in the fasting blood sample output in mmol/L
Measured: At the start of OGTT.
HDL Cholesterol
HDL Cholesterol measured in the fasting blood sample and output in mmol/L
Measured: At the start of OGTT
LDL Cholesterol
LDL cholesterol measured in the fasting blood sample and output in mmol/L
Measured: At the start of OGTT
Triglycerides
Triglycerides measured in the fasting blood sample and output as mmol/L
Measured: At the start of OGTT
Cholesterol/HDL Ratio
Ratio of fasting blood Cholesterol value and HDL cholesterol value output as a unitless number.
Measured: At the start of OGTT
Total Protein
Total Protein measured in Fasting Blood Sample and output as g/L
Measured: At the start of OGTT
Albumin
Albumin measured in the Fasting Blood Sample and output as g/L
Measured: At the start of OGTT
Globulin
Globulin measured in the Fasting Blood Sample and output as g/L
Measured: At the start of OGTT
A/G ratio
Ratio of Albumin and Globulin measured in the Fasting Blood Sample, unitless output.
Measured: At the start of OGTT
Bilirubin, total
Bilirubin, total measured in the Fasting Blood Sample and output as umol/L
Measured: At the start of OGTT
Bilirubin, direct
Bilirubin, direct measured in the Fasting Blood Sample and output as umol/L
Measured: At the start of OGTT
Bilirubin, indirect
Bilirubin, indirect measured in the Fasting Blood Sample and output as umol/L
Measured: At the start of OGTT
Alkaline Phosphatase
Alkaline Phosphatase measured in Fasting Blood Sample and output as U/L
Measured: At the start of OGTT
SGPT/ALT
Serum Glutamic Pyruvic Transaminase / Alanine Aminotransferase measured in Fasting Blood Sample and output as U/L
Measured: At the start of OGTT
SGOT/AST
Serum glutamic-oxaloacetic transaminase/Aspartate aminotransferase measured in Fasting Blood Sample and output in U/L
Measured: At the start of OGTT
Gamma GT
Gamma-glutamyl transferase measured in Fasting Blood Sample and output in U/L
Measured: At the start of OGTT
Phosphate
Phosphate measured in the Fasting Blood Sample and output as mmol/L
Measured: At the start of OGTT
Calcium
Calcium measured in the Fasting Blood Sample and output as mmol/L
Measured: At the start of OGTT
Uric Acid
Uric Acid measured in the Fasting Blood Sample and output as mmol/L
Measured: At the start of OGTT
Rheumatoid Factor
Rheumatoid Factor measured in the Fasting Blood Sample and output as IU/ml
Measured: At the start of OGTT
Sodium
Sodium measured in Fasting Blood Sample and output as mmol/L
Measured: At the start of OGTT
Potassium
Potassium measured in the Fasting Blood Sample and output as mmol/L
Measured: At the start of OGTT
Chloride
Chloride measured in Fasting Blood Sample and output in mmol/L
Measured: At start of OGTT
Urea
Urea measured in Fasting Blood Sample and output as mmol/L
Measured: At start of OGTT
Creatinine
Creatinine measured in Fasting Blood Sample and output as umol/L
Measured: At start of OGTT
eGFR
eGFR measured in Fasting Blood Sample and output as ml/min/1.73m^2
Measured: At Start of OGTT
Free T4
Free T4 measured in the Fasting Blood Sample and output as pmol/L.
Measured: At the start of OGTT
TSH
TSH measured in Fasting Blood Sample and output as mIU/L
Measured: At the start of OGTT
Haemoglobin
Haemoglobin measured in Fasting Blood sample and output as g/dL
Measured: At the start of the OGTT
Red cell count
Red cell count measured in the Fasting Blood Sample and output as x10^12/L
Measured: At the start of the OGTT
Total White cell count
Total White cell count measured in the Fasting Blood Sample and output as x10^9/L.
Measured: At the start of the OGTT
Neutrophils
Neutrophils measured in the Fasting Blood Samples and output as both % and x10^9/L.
Measured: At the start of the OGTT
Lymphocytes
Lymphocytes measured in the Fasting Blood Sample and output as both % and x10^9/L
Measured: At the start of the OGTT
Monocytes
Monocytes measured in the Fasting Blood Sample and output as both % and x10^9/L
Measured: At the start of the OGTT
Eosinophils
Eosinophils measured in the Fasting Blood Samples and output as both % and x10^9/L
Measured: At the start of the OGTT
Basophils
Basophils measured in the Fasting Blood Sample and output in both % and x10^9/L
Measured: At the start of the OGTT
Haematocrit (PCV)
Haematocrit (PCV) measured in Fasting Blood Sample and output in a unitless format.
Measured: At the start of the OGTT
MCV
MCV measured in the Fasting Blood Sample and output as fL.
Measured: At the start of the OGTT
MCH
MCH measured in the Fasting Blood Sample and output as pg.
Measured: At the start of the OGTT
MCHC
MCHC measured in the fasting blood sample and output as g/dL
Measured: At the start of the OGTT
RDW
RDW measured in the Fasting Blood Sample and output as %
Measured: At the start of the OGTT
Platelets
Platelets measured in the Fasting Blood Sample and output in x10^9/L
Measured: At the start of the OGTT
Peripheral Blood Film
Peripheral Blood Film analyzed from the Fasting Blood Sample and described verbally.
Measured: At the Start of the OGTT.
NT-ProBNP
NT-ProBNP measured from the Fasting Blood Sample and output in pg/ml
Measured: At the start of the OGTT
hs Troponin-I
hs Troponin-I measured in the Fasting Blood Sample and output in pg/ml
Measured: At the start of the OGTT
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Oct 2026
- Study start27 Jul 2026
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Diabete MellitusStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 270 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University Health System, Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jocelyn Chew, National University Health System, Singapore
- Investigators
- Roger Sik Yin Foo, MD, Principal investigator, National University of Singapore (NUS), National University Hospital (NUH)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07861191
- Sponsor's protocol ID
- NUS-IRB-2025-740
- Acronym
- RESET-INSPIRE
- Status last verified
- Oct 2026
- First submitted
- 25 Sep 2026
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975.
PubMed 28118453Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Norgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8.
PubMed 31177185Wang D, Mu SZ, Tang O, Echouffo-Tcheugui JB, Mitchell CM, Fang M, Rooney MR, Yeh HC, Rebholz CM, Pilla SJ, Appel LJ, Selvin E. Design of the Continuous Glucose Monitoring (CGM) Study in the Dietary Approaches to Stop Hypertension for Diabetes Trial (DASH4D-CGM). Contemp Clin Trials. 2025 Apr;151:107845. doi: 10.1016/j.cct.2025.107845. Epub 2025 Feb 12.
PubMed 39952551
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- RESET-INSPIRE Study: Insulin Sensitivity & Population Intervention With Real-time Evaluation Using CGM
- ClinicalTrials.gov ID
- NCT07861191
- Acronym / sponsor ID
- RESET-INSPIRE / NUS-IRB-2025-740
- Conditions
- Diabete Mellitus, MASLD
- Keywords
- insulin resistance, Insulin sensitivity, Continuous Glucose Monitor, OGTT, MASLD, Cardiovascular Metabolic Disease, Prediabetes, Diabetes
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 270 participants (estimated)
- Lead sponsor
- National University Health System, SingaporeUniversity, hospital or other
- Study start
- 27 Jul 2026 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 6 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The RESET-INSPIRE study is designed to investigate individual variability in glucose response and insulin sensitivity, a key mechanism underlying metabolic-associated steatotic liver disease (MASLD) and cardiometabolic disorders. Building on findings from Project RESET, this study aims to develop and validate a continuous glucose monitoring (CGM)-based approach for assessing insulin sensitivity.
Detailed description
Insulin resistance is a key factor in the development of metabolic-associated steatotic liver disease (MASLD) and cardiovascular-metabolic disease (CVMD). It occurs when tissues such as skeletal muscle, fat, and liver respond poorly to insulin, leading to metabolic imbalance.
In skeletal muscle, insulin resistance reduces glucose uptake after meals, leaving blood sugar elevated for longer. This contributes to stress on pancreatic beta-cells and damages blood vessels and the heart. In adipose tissue, impaired insulin action increases the release of free fatty acids, which build up in the liver, muscle, and heart, worsening fat accumulation and mitochondrial dysfunction. In the liver, insulin resistance prevents proper suppression of glucose production, causing fasting hyperglycemia and accelerating progression to diabetes.
Together, these tissue-specific changes drive hyperglycemia, abnormal lipid levels, inflammation, and vascular dysfunction-hallmarks of metabolic syndrome. Early detection and targeted management of insulin resistance are therefore crucial for preventing MASLD and CVMD This study will enable evaluation of CGM-derived metrics against established OGTT-based measures, providing insights into early metabolic dysfunction in individuals without diabetes under both controlled and real-world conditions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Main Study Cohort | – | –There is only one study cohort for Project Inspire, and no interventions are done on them as this is an Observational study. |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Recruitment is in Singapore as follows: 1. Flyer: The flyer, which contains a QR code to our landing page and the study contact number, will be distributed at various outreach events such as the Standard Chartered Marathon Race Pack Collection. Permissions will be obtained from the event organizers (if necessary, especially for non-NUS events), before distribution of flyers. 2. Word of Mouth: We are planning to inform participants of Project RESET about this study and encourage them to inform their family and friends to participate in it. 3. Project RESET Cohort: About 5000 people have signed up for Project RESET and we can look to recruit these people for this study if they have given their consent to be contacted for other studies. 4. Expression of interest online form: There was an online Town Hall conducted for all Project RESET participants on 11th and 12th of February 2026 and Project INSPIRE was introduced there with a link and QR code to Project INSPIRE.
Key inclusion criteria (6 listed)
- Adults aged between 21 and 70 years (including 70 yrs old) at the time of screening
- Able to speak and understand English
- No past history of acute myocardial infarction (heart attack), stroke or heart failure
- Able to understand and voluntarily provide written informed consent prior to any study specific procedures.
- No current diagnosis of type 1 or type 2 diabetes, and not taking glucose-lowering medications.
Key exclusion criteria (8 listed)
- Known diagnosis of diabetes mellitus (type 1 or type 2), or use of antidiabetic medication.
- Current or recent (within 3 months) use of medications known to affect glucose, including but not limited to corticosteroids.
- Known history of liver disease or abnormal liver function deemed clinically significant by the investigator who is a medical doctor.
- Renal impairment, defined as eGFR ≤ 60mL/min/1.73m^2
- Known pregnancy, plans to become pregnant during the study period, or currently breastfeeding, or
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Continuous Glucose Monitor data
Time frame: 15 days
The continuous Glucose Monitor measures glucose in the interstitial fluid under the skin and outputs it in units of mmol/L
Blood Glucose
Time frame: 2 hours
Blood glucose is measured at all timepoints for the OGTT and is output in mmol/L
Insulin
Time frame: 2 hours
Insulin in the blood is measured at all timepoints of the OGTT and output in mU/L
C-Peptide
Time frame: 2 hours
C-Peptide levels in the blood is measured at all timepoints of the OGTT and output as ng/ml
48 secondary outcomes
HBA1C
Time frame: At the start of OGTT
hs-CRP
Time frame: At the start of the OGTT
ESR (Alifax)
Time frame: At the start of OGTT
Total Cholesterol
Time frame: At the start of OGTT.
HDL Cholesterol
Time frame: At the start of OGTT
LDL Cholesterol
Time frame: At the start of OGTT
Triglycerides
Time frame: At the start of OGTT
Cholesterol/HDL Ratio
Time frame: At the start of OGTT
Total Protein
Time frame: At the start of OGTT
Albumin
Time frame: At the start of OGTT
Globulin
Time frame: At the start of OGTT
A/G ratio
Time frame: At the start of OGTT
Bilirubin, total
Time frame: At the start of OGTT
Bilirubin, direct
Time frame: At the start of OGTT
Bilirubin, indirect
Time frame: At the start of OGTT
Alkaline Phosphatase
Time frame: At the start of OGTT
SGPT/ALT
Time frame: At the start of OGTT
SGOT/AST
Time frame: At the start of OGTT
Gamma GT
Time frame: At the start of OGTT
Phosphate
Time frame: At the start of OGTT
Calcium
Time frame: At the start of OGTT
Uric Acid
Time frame: At the start of OGTT
Rheumatoid Factor
Time frame: At the start of OGTT
Sodium
Time frame: At the start of OGTT
Potassium
Time frame: At the start of OGTT
Chloride
Time frame: At start of OGTT
Urea
Time frame: At start of OGTT
Creatinine
Time frame: At start of OGTT
eGFR
Time frame: At Start of OGTT
Free T4
Time frame: At the start of OGTT
TSH
Time frame: At the start of OGTT
Haemoglobin
Time frame: At the start of the OGTT
Red cell count
Time frame: At the start of the OGTT
Total White cell count
Time frame: At the start of the OGTT
Neutrophils
Time frame: At the start of the OGTT
Lymphocytes
Time frame: At the start of the OGTT
Monocytes
Time frame: At the start of the OGTT
Eosinophils
Time frame: At the start of the OGTT
Basophils
Time frame: At the start of the OGTT
Haematocrit (PCV)
Time frame: At the start of the OGTT
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Background: PubMed 28118453Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, Kollman C, Kruger D, McGill JB, Polonsky W, Toschi E, Wolpert H, Price D; DIAMOND Study Group. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial. JAMA. 2017 Jan 24;317(4):371-378. doi: 10.1001/jama.2016.19975.
- Background: PubMed 31177185Battelino T, Danne T, Bergenstal RM, Amiel SA, Beck R, Biester T, Bosi E, Buckingham BA, Cefalu WT, Close KL, Cobelli C, Dassau E, DeVries JH, Donaghue KC, Dovc K, Doyle FJ 3rd, Garg S, Grunberger G, Heller S, Heinemann L, Hirsch IB, Hovorka R, Jia W, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Levine B, Mayorov A, Mathieu C, Murphy HR, Nimri R, Norgaard K, Parkin CG, Renard E, Rodbard D, Saboo B, Schatz D, Stoner K, Urakami T, Weinzimer SA, Phillip M. Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care. 2019 Aug;42(8):1593-1603. doi: 10.2337/dci19-0028. Epub 2019 Jun 8.
- Background: PubMed 39952551Wang D, Mu SZ, Tang O, Echouffo-Tcheugui JB, Mitchell CM, Fang M, Rooney MR, Yeh HC, Rebholz CM, Pilla SJ, Appel LJ, Selvin E. Design of the Continuous Glucose Monitoring (CGM) Study in the Dietary Approaches to Stop Hypertension for Diabetes Trial (DASH4D-CGM). Contemp Clin Trials. 2025 Apr;151:107845. doi: 10.1016/j.cct.2025.107845. Epub 2025 Feb 12.
Related trials for Diabete Mellitus
Recruiting
Using Ultromics EchoGo HFpEF Algorithm to Identify and Treat High Heart Failure Risk in Patients With Type 2 Diabetes
Heart Failure, Diabetes
Not yet recruiting
STRONG: SMART Trial
Gestational Diabetes Mellitus (GDM)
Recruiting
Continuous Glucose Monitoring Systems in People With Type 2 Diabetes Not Treated With Insulin
Type 2 Diabetes
Active, not recruitingPhase 4
Pentoxifylline in Diabetic Kidney Disease
Diabetic Kidney Disease
Not yet recruiting
Inter-Arm Differences in Continuous Glucose Monitor Readings in Adults With Diabetes
Continuous Glucose Monitoring, Type 1 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Roger Sik Yin Foo, MD principal investigator
National University of Singapore (NUS), National University Hospital (NUH)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabete Mellitus and MASLD, run by National University Health System, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Benjamin Jia-Hui Loh, PhD (+65-89430875, benjaminloh82@nus.edu.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Continuous Glucose Monitor data (time frame: 15 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT07861191, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.